Peptides DB
Research-centric peptide and protocol reference hub
Study 2 of 10Adipotide (Prohibitin-TP01) literatureJournal of substance use and addiction treatment · RCT2026

"It was good because they have a relationship with us": A qualitative study on low-threshold buprenorphine treatment at syringe services programs.

Syringe service programs can effectively initiate buprenorphine treatment, but managing precipitated withdrawal and fostering strong provider relationships are critical for success.

Read at Journal of substance use and addiction treatmentAdd to compare

Where it sits

this study against the rest of the adipotide (prohibitin-tp01) corpus
3
Preclinical
4
Observational
0
Open-label
2
Randomised · this one
1
Reviews

Summary and findings

The study explored patients' experiences with buprenorphine treatment initiated at syringe service programs (SSPs) for opioid use disorder. It involved 12 participants who completed qualitative exit interviews after a randomized controlled trial. Participants reported both benefits and challenges of SSP-based treatment, including the importance of strong relationships with healthcare providers.

How much of this paper we could read: full text read (0.70). We had a clear abstract, so the summary below closely tracks the paper. What this means →
n=122026

Abstract

The authors’ words, as Journal of substance use and addiction treatment supplied them

<h4>Introduction</h4>Syringe service programs (SSPs) reach people who inject drugs with opioid use disorder (OUD) and are novel "low-threshold" venues to initiate buprenorphine treatment. The study investigated patients' experiences with SSP-initiated buprenorphine treatment, which could aid in improving buprenorphine treatment delivery at SSPs.<h4>Methods</h4>The study included 12 participants who completed qualitative exit interviews after a randomized controlled trial of buprenorphine treatment at SSPs. In the parent study, participants received buprenorphine treatment through an onsite model at an SSP or enhanced referral to a community health center based on the randomization sequence. Most participants started taking buprenorphine at home. Exit interviews included participants from both study arms, and the semi-structured interview guide focused on their experiences with clinicians, experiences initiating buprenorphine, prior experiences with OUD treatment, and perceptions about continuing buprenorphine treatment. Four researchers iteratively read, coded, and discussed each transcript, then they derived recurring themes using thematic analysis.<h4>Results</h4>Participants were mostly male, middle-aged, and 50% identified as Latino. Four main themes related to buprenorphine treatment initiation: 1) Onsite treatment facilitated buprenorphine prescription, but some participants also expressed a need for additional support; 2) Precipitated withdrawal complicated participants' buprenorphine initiation in both arms; 3) Participants largely experienced the SSPs as affirming and welcoming; and 4) Developing strong relationships with healthcare providers was critical to successful buprenorphine treatment initiation.<h4>Conclusions</h4>The SSP-based model provided rapid access to buprenorphine prescriptions, but precipitated withdrawal was a common complication. Some participants desired additional support and guidance when they started taking buprenorphine at home. The findings point to a "low-threshold, high-touch" approach where participants receive expedited access to buprenorphine providers at SSPs but also additional support throughout the initiation process to avoid and/or manage precipitated withdrawal. Despite some challenges, SSP-based buprenorphine treatment was highly valued by study participants.

Background

The study addresses the potential of syringe service programs (SSPs) as venues for initiating buprenorphine treatment for opioid use disorder (OUD). SSPs are considered novel 'low-threshold' settings that can reach individuals who inject drugs. Understanding patient experiences in these settings is crucial for optimizing treatment delivery and addressing barriers to care.

Methods

This qualitative study involved 12 participants who completed exit interviews after a randomized controlled trial of buprenorphine treatment at SSPs. Participants were randomized to receive either onsite buprenorphine treatment at an SSP or enhanced referral to a community health center. The semi-structured interviews explored experiences with clinicians, initiation of buprenorphine, prior OUD treatment, and perceptions of ongoing treatment.

Results

Participants highlighted four main themes regarding buprenorphine initiation: onsite treatment facilitated access to prescriptions, but additional support was needed; precipitated withdrawal was a complication; SSPs were perceived as affirming environments; and strong relationships with healthcare providers were essential for successful treatment initiation. The SSP model provided rapid access to buprenorphine, but managing precipitated withdrawal remained a challenge.

Interpretation

The findings suggest that SSPs can effectively facilitate buprenorphine initiation, but additional support is necessary to manage complications like precipitated withdrawal. The study underscores the importance of strong provider-patient relationships in treatment success. While the qualitative insights are valuable, the small sample size and subjective nature of the data limit the ability to generalize findings to broader populations.

Key findings

  • 12 participants completed qualitative exit interviews.
  • 50% of participants identified as Latino.
  • Onsite treatment facilitated buprenorphine prescription.
  • Precipitated withdrawal was a common complication.
  • Strong relationships with healthcare providers were critical.

Limitations

  • small n=12
  • qualitative study limits generalizability
  • subjective data from exit interviews
  • no quantitative outcome measures

Elsewhere in the Adipotide (Prohibitin-TP01) corpus

CTwf1 regulates adipocyte proliferation and differentiation through Yap nucleus accumulation.Adipocyte · 2026 · 2.28-fold vs. control for proliferation with Twf1 knockdown.AnimalCThe effects of varying dietary electrolyte balance levels in canola meal-based diets on growth performance, ascites susceptibility, and nutrient digestibility in cold-stressed broilers.Veterinary and animal science · 2026 · n=360 · Not reported in abstract.AnimalCDietary sublancin or oregano essential oil enhances growth and immunity in goat kids via modulating colonic microbiota and bile acids.Animal nutrition (Zhongguo xu mu shou yi xue hui) · 2026 · n=24 · Increased average daily gain (ADG) with OEO and sublancin supplementation, P < 0.05.AnimalCZinc oxide quantum dots as an alternative to conventional ZnO: Physicochemical characterization and its application in weaned piglets.Animal nutrition (Zhongguo xu mu shou yi xue hui) · 2025 · n=150 · Average daily gain (ADG) improved with ZnO, ZnO QDs 250 and ZnO QDs 500 groups, P = 0.003.AnimalCEffects of clove extract and hydrolyzed whey peptides supplementation on health, performance and blood parameters of suckling dairy calves.Veterinary and animal science · 2026 · n=100 · Red blood cell count differed among treatments, with control group having higher RBC concentration compared to clove extract, hydrolyzed whey protein, or their combination (P = 0.048).AnimalDUpgrading the feeding value of oil palm fronds for ruminants through processing: Evidence from a meta-analysis of &lt;i&gt;in vitro&lt;/i&gt; and &lt;i&gt;in vivo&lt;/i&gt; studies.Veterinary and animal science · 2018 · Not reported in abstract.review